A Phase I/II Study of SU011248 (Sutent) in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Patients With Stage IV Colorectal Cancer
Phase of Trial: Phase I/II
Latest Information Update: 20 Feb 2017
At a glance
- Drugs Sunitinib (Primary) ; Cetuximab; Irinotecan
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- 16 Feb 2017 Status changed from active, no longer recruiting to discontinued.
- 02 Jan 2008 Status changed from recruiting to in progress.
- 08 Nov 2006 New trial record.